Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics (NASDAQ: ACRS) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Initiation of Phase 2a study activities for ATI-2138 in atopic dermatitis.
2. Strengthened balance sheet through sale of future OLUMIANT® royalties for up to $31.5 million.
3. Q2 2024 net loss of $11.0 million, compared to $29.6 million in Q2 2023.
4. Total revenue increased to $2.8 million in Q2 2024 from $1.9 million in Q2 2023.
5. R&D expenses decreased to $8.8 million from $25.3 million year-over-year.
6. Cash, cash equivalents, and marketable securities of $149.9 million as of June 30, 2024.
The company expects its current cash position, including the $26.5 million from the OLUMIANT® royalty sale, to fund operations into 2028.
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. This non-dilutive transaction strengthens Aclaris' balance sheet, providing financial flexibility to pursue value-creating opportunities and invest in internal programs. OMERS acquires a portion of the royalty for worldwide net sales of OLUMIANT for alopecia areata from April 1, 2024, through the remainder of the royalty term, as well as 100% of the remaining anniversary milestone payments from Eli Lilly.
Aclaris Therapeutics (NASDAQ: ACRS) announced that Dr. Neal Walker, Interim President & CEO, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place on June 11, 2024, at 11:20 AM ET in Miami, Florida.
The chat will be webcasted and accessible via the company's website, where it will be archived for at least 30 days.
Aclaris Therapeutics reported its financial results for the first quarter of 2024 and provided a corporate update. The company is progressing ATI-2138 into a Phase 2a trial for atopic dermatitis. Aclaris also announced positive results for its various ITK inhibitor programs and highlighted financial data showing a decrease in net loss and revenue. The company anticipates lower cash expenditures in future quarters due to ongoing strategic reviews.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will announce its first quarter 2024 financial results on May 7, 2024. The company focuses on developing drug candidates for immuno-inflammatory diseases. A conference call will follow to provide a corporate update.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.